MiRNA marker and kit for diagnosing and evaluating myocardial aging and application of miRNA marker and kit
By detecting the expression level of hsa-miR-186-5p, kits and primers for diagnosis of myocardial aging are provided, which solves the problem of inaccurate diagnosis of central muscle aging in the prior art, and achieves efficient identification and evaluation of myocardial aging. and show its potential as a therapeutic target.
Patent Information
- Application Number
- CN202411330291.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing diagnosis methods for myocardial aging are not accurate and convenient enough, making it difficult to identify and intervene with myocardial aging-related diseases early, especially in the elderly population, which cannot fully detect subtle changes in the heart.
Using hsa-miR-186-5p as a new marker of myocardial aging, by detecting its expression level, it provides kits and primers for diagnosing, screening, evaluating and distinguishing myocardial aging from other heart diseases, combined with RT-PCR, Real-time quantitative PCR, in situ hybridization, chip or high-throughput sequencing platform for detection of hsa-miR-186-5p expression levels.
The significant upregulation of hsa-miR-186-5p has been verified in patients with myocardial aging, with excellent sensitivity and specificity, which can effectively diagnose myocardial aging, and its expression level is positively correlated with cardiomyocyte aging and BNP levels, indicating that it is in myocardial myocardial aging. There is good potential in the diagnosis and evaluation of aging and may serve as a therapeutic target for myocardial aging.
Smart Images

Figure CN119082291A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a marker for diagnosing myocardial aging, specifically a miRNA marker, and also relates to a kit for detecting the miRNA marker and application thereof, belonging to the field of medical molecular diagnosis. Background Art
[0002] Aging is a natural physiological process that accompanies an organism throughout its life from birth to death. This process is determined by genetic programs, but is also significantly affected by environmental factors, including eating habits, lifestyle, disease, and stress. Therefore, the aging rate of different individuals may vary greatly. At the physiological level, aging is manifested as a gradual decline in the functions of multiple organs and systems, which is particularly evident in cardiovascular diseases, including myocardial diseases and coronary artery diseases, which increase in incidence with age. In the context of an aging population, it is particularly important to improve the ability to diagnose and treat myocardial aging-related diseases. At present, the diagnostic methods for myocardial aging are not accurate and convenient enough. Therefore, the development of new diagnostic technologies and methods to identify and intervene in myocardial aging earlier is an important direction of current research.
[0003] Physiological changes of cardiac aging include increased left ventricular wall thickness and decreased diastolic function, which are usually independent of traditional cardiovascular risk factors such as smoking, hypertension, dyslipidemia, and diabetes. With aging, in order to compensate for the reduced filling caused by increased left ventricular wall thickness, the contractility and pressure of the atria gradually increase, which may lead to atrial hypertrophy and increased risk of atrial fibrillation. These early changes in diastolic function of the heart are very common in the elderly population, but current diagnostic techniques may not be able to fully detect these subtle changes. Therefore, new diagnostic tools need to be developed to more accurately assess the pathophysiological changes of myocardial aging.
[0004] MicroRNAs (miRNAs) are a class of small noncoding RNA molecules that regulate gene expression by binding to messenger RNA (mRNA), usually inhibiting the translation process of proteins. The seed sequence of miRNAs is short, about 6 nucleotides, which enables them to regulate multiple signaling pathways and their downstream target genes. miRNAs play a role in a variety of biological processes, including cell proliferation, differentiation, apoptosis, and tissue regeneration. Due to the versatility of miRNAs, their dysregulation is associated with the occurrence and development of a variety of diseases, especially in cardiovascular diseases. Research on miRNAs as therapeutic targets is ongoing, including exploring their potential for therapeutic silencing. However, due to the wide distribution of miRNAs in organisms and the fact that one miRNA may regulate multiple mRNA targets, it remains challenging to precisely elucidate the specific mechanism of action of each miRNA. There are relatively few studies on miRNAs as diagnostic and therapeutic targets for myocardial aging, but in-depth research in this field may provide new strategies and methods for the clinical diagnosis and treatment of myocardial aging. Summary of the invention
[0005] The primary technical problem to be solved by the present invention is to provide a new application of miRNA markers. The miRNA markers can not only be used to prepare substances for diagnosis, screening, disease assessment and differentiation of myocardial aging and other heart diseases, but also become new targets for the treatment of myocardial aging-related diseases.
[0006] Another technical problem to be solved by the present invention is to provide a kit for detecting the miRNA marker. The kit can be used for diagnosing, screening, evaluating and distinguishing myocardial aging from other heart diseases.
[0007] The third technical problem to be solved by the present invention is to provide a primer for detecting the miRNA marker. The primer can be used for diagnosing, screening, evaluating and distinguishing myocardial aging from other heart diseases.
[0008] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:
[0009] According to a first aspect of an embodiment of the present invention, there is provided an application of a substance for detecting miRNA markers, including one or more of the following applications:
[0010] A1) Application in the preparation of products for diagnosing myocardial aging;
[0011] A2) Application in the preparation of products for screening myocardial aging;
[0012] A3) Application in the preparation of products for treating myocardial aging;
[0013] A4) Application in the preparation of myocardial aging condition assessment products;
[0014] A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases;
[0015] The miRNA marker is hsa-miR-186-5p, and the nucleotide sequence is shown in SEQ ID No.1.
[0016] The "product" can be a product for diagnosing myocardial aging by detecting the expression level of hsa-miR-186-5p through RT-PCR, real-time quantitative PCR, in situ hybridization, chip or high-throughput sequencing platform.
[0017] In the above applications, hsa-miR-186-5p expression was significantly upregulated in the plasma samples of patients with myocardial aging; the expression level of hsa-miR-186-5p in healthy people was significantly lower than that in patients with myocardial aging.
[0018] Preferably, the substance is a reagent for detecting the expression level of hsa-miR-186-5p, or a reagent for specifically identifying hsa-miR-186-5p, or a reagent for detecting the content of hsa-miR-186-5p.
[0019] Preferably, the substance is a substance for detecting hsa-miR-186-5p, specifically the following a), b) or c)
[0020] a) primers for detecting or specifically recognizing hsa-miR-186-5p;
[0021] b) a reagent set containing the reagent described in a);
[0022] c) A kit containing a) or b).
[0023] Preferably, the primers are the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.3.
[0024] According to a second aspect of an embodiment of the present invention, a kit for detecting miRNA markers is provided, wherein the kit comprises one or more of the following applications:
[0025] A1) Application in the preparation of products for diagnosing myocardial aging;
[0026] A2) Application in the preparation of products for screening myocardial aging;
[0027] A3) Application in the preparation of products for treating myocardial aging;
[0028] A4) Application in the preparation of myocardial aging condition assessment products;
[0029] A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases;
[0030] The miRNA marker is hsa-miR-186-5p, and the nucleotide sequence is shown in SEQ ID No.1; the kit includes a reagent for detecting or specifically identifying hsa-miR-186-5p, or a reagent for detecting the expression level of hsa-miR-186-5p.
[0031] The kit provided by the present invention can be used to detect the expression of the hsa-miR-186-5p characteristic gene sequence shown in SEQ ID NO.1 in the peripheral blood of the subject, and then the probability of myocardial aging in the subject can be determined based on the information of up-regulation or down-regulation of the gene expression, thereby achieving the diagnosis of myocardial aging.
[0032] The kit provided by the present invention may include appropriate packaging and instructions for use in the method disclosed by the present invention. Preferably, the detection kit provided by the present invention is a nucleic acid detection kit, including reagents required for RNA extraction and real-time fluorescence quantitative PCR (qRT-PCR). The kit may further include appropriate buffer and polymerase, and may also include control primers and / or probes.
[0033] Preferably, the reagent for detecting or specifically identifying hsa-miR-186-5p is a specific primer, and the specific primer is the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.3.
[0034] According to a third aspect of an embodiment of the present invention, a primer for detecting a miRNA marker is provided, wherein the primer comprises one or more of the following applications:
[0035] A1) Application in the preparation of products for diagnosing myocardial aging;
[0036] A2) Application in the preparation of products for screening myocardial aging;
[0037] A3) Application in the preparation of products for treating myocardial aging;
[0038] A4) Application in the preparation of myocardial aging condition assessment products;
[0039] A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases;
[0040] The primers are primers for detecting the expression level of hsa-miR-186-5p or specifically identifying hsa-miR-186-5p.
[0041] Preferably, the primers are the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.3.
[0042] Compared with the prior art, the present invention has the following technical effects:
[0043] (1) The present invention provides hsa-miR-186-5p as a new biomarker for the diagnosis of myocardial aging. In a clinical validation trial, the expression of hsa-miR-186-5p in the plasma of patients with myocardial aging was significantly increased compared with that in the healthy control group. This finding indicates that hsa-miR-186-5p is a potential biomarker for myocardial aging, which is suitable for the diagnosis, screening, and evaluation of myocardial aging and differentiation from other heart diseases.
[0044] (2) The efficacy of hsa-miR-186-5p in diagnosing myocardial aging was verified by ROC curve analysis, showing that the molecule has excellent sensitivity and specificity, thus confirming its good potential as a diagnostic tool. In addition, the expression level of beta-galactosidase, a marker of myocardial cell aging, was positively correlated with that of hsa-miR-186-5p. This correlation further confirmed the close relationship between hsa-miR-186-5p and myocardial aging and indicated its effectiveness in diagnosing myocardial aging.
[0045] (3) In clinical experiments, the expression of BNP (B-type natriuretic peptide) in plasma was also positively correlated with that of hsa-miR-186-5p. BNP is a peptide hormone synthesized by the heart when the ventricular wall is dilated or stretched, and is often used to assess the compensatory function of the heart and diagnose heart failure. Therefore, the positive correlation between hsa-miR-186-5p and BNP levels indicates that the plasma level of hsa-miR-186-5p can reflect the severity of myocardial aging, suggesting that hsa-miR-186-5p can be used in the development of products for assessing myocardial aging.
[0046] (4) In an in vitro cellular validation experiment, AC16 cardiomyocytes treated with D-galactose (D-gal) showed an increase in the expression of hsa-miR-186-5p, indicating that the level of hsa-miR-186-5p increases during cardiomyocyte aging. This finding provides a cellular and molecular basis for hsa-miR-186-5p as a diagnostic biomarker for myocardial aging. In a D-gal-induced cell aging model, knocking down hsa-miR-186-5p can alleviate aging, further proving that hsa-miR-186-5p is not only a potential diagnostic biomarker for myocardial aging, but also a potential new target for the treatment of myocardial aging. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 The heat map of the difference in miRNA expression between aging cardiomyocytes AC 16 and normal controls obtained by sequencing;
[0048] Figure 2 To determine the hsa-miR-186-5p content in the plasma of patients with myocardial aging and normal controls by qRT-PCR;
[0049] Figure 3 ROC curve for hsa-miR-186-5p in diagnosing patients with myocardial aging;
[0050] Figure 4 The relationship between the positive ratio of β-galactosidase, a marker of senescence, and the expression level of hsa-miR-186-5p in cardiomyocytes induced by D-gal;
[0051] Figure 5 The relationship between BNP and hsa-miR-186-5p expression in patients;
[0052] Fig. 6A is a graph of hsa-miR-186-5p expression levels after AC16 was transfected with hsa-miR-186-5p small interfering RNA (siRNA);
[0053] Figure 6B is a graph of mRNA expression levels after AC16 was transfected with hsa-miR-186-5p small interfering RNA (siRNA);
[0054] Fig. 7A The expression of P21 mRNA in D-gal-induced cardiomyocytes after siRNA knockdown of hsa-miR-186-5p in AC16 cells;
[0055] Figure 7B The expression of IL-1β mRNA in cardiomyocytes induced by D-gal after siRNA knockdown of hsa-miR-186-5p in AC16 cells;
[0056] Figure 8 The expression of BNP in the cell supernatant of hsa-miR-186-5p knockdown group and control group AC16 after treatment with D-gal;
[0057] Fig. 9A This is a diagram showing the cell cycle of normal cells after inducing cell senescence using the senescence-inducing reagent D-gal by flow cytometry;
[0058] Fig. 9B This is a diagram showing the cell cycle status after knockdown of hsa-miR-186-5p and induction of cell senescence using the senescence-inducing reagent D-gal as measured by flow cytometry. DETAILED DESCRIPTION
[0059] The present invention is further described below in conjunction with specific examples. These examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually performed under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise defined, all professional and scientific terms used in the text have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to the described contents can be applied to the method provided by the present invention. The preferred implementation methods and materials described in the text are for demonstration purposes only.
[0060] The research and development process and ideas of the present invention: First, total RNA was extracted from 3 naturally aged AC16 cardiomyocytes and 3 normal control cells, and sent to Guangzhou Epigenetics for miRNA sequencing. Through analysis, miRNAs with significant differences in expression levels (Fold change ≥ 2.0, P value < 0.05) were screened out. Subsequently, the qRT-PCR technology was used to determine the contents of the top 10 miRNAs in the sequencing results in the patient's plasma, and the first miRNA with a significantly increased expression level was selected for subsequent experiments. In order to further verify the relationship between hsa-miR-186-5p and myocardial aging, the inventors also conducted experiments at the in vitro cell level, thereby confirming the potential of hsa-miR-186-5p as a biomarker for myocardial aging at the molecular level.
[0061] Example 1 Screening and correlation study of myocardial aging miRNA markers
[0062] 1. Sample and Methods:
[0063] 1.1 Clinical samples:
[0064] Venous blood was collected from 50 patients aged 60 to 90 years who were hospitalized in the General Hospital of the Chinese People's Liberation Army from 2020 to 2023 and excluded heart disease. Venous blood was also collected from 50 healthy subjects aged ≤ 30 years. They were divided into two groups: a control group and an aging group for subsequent determination of plasma miRNA levels.
[0065] Inclusion criteria:
[0066] (1) Inpatients aged 60 years or younger and younger than 90 years;
[0067] (2) Healthy subjects aged ≤30 years old;
[0068] (3) Complete blood sample information is available.
[0069] Exclusion criteria: malignant tumors, severe liver and kidney dysfunction, severe autoimmune diseases, severe blood system diseases or cardiovascular diseases such as coronary heart disease, valvular heart disease and cardiomyopathy. 1.2 Methods:
[0070] 1.2.1 Plasma extraction: Human peripheral blood was collected using EDTA anticoagulant blood collection tubes, centrifuged at 2500 g for 15 min, and the upper plasma was collected into a 2 ml sterile tube and stored in a -80 °C refrigerator.
[0071] 1.2.2 RNA extraction and real-time fluorescence quantitative PCR (qRT-PCR):
[0072] Total RNA was extracted from AC16 using RNA Spectrum Total RNA Kit (DP419, TIANGEN, Beijing, China).
[0073] (1) RNA extraction
[0074] To extract tissue RNA from plasma samples, we followed the instructions for use of TRIZOL Reagent (Invitrogen). First, 1 ml of TRIZOL Reagent and 200 μl of chloroform were added to the plasma, followed by shaking for 20 seconds and standing at room temperature for 10 minutes. Next, centrifugation was performed at 13,000 rpm for 15 minutes at 4°C. The supernatant was carefully aspirated, and 800 μl of isopropanol was added, gently inverted to mix, and then stood at -20°C for 1 hour. Centrifugation was performed again at 13,000 rpm and 4°C for 15 minutes, and the supernatant was discarded. After that, 1 ml of 75% ethanol was added to gently wash the precipitate, centrifuged at 13,000 rpm and 4°C for 5 minutes, and the supernatant was removed and blown dry. Finally, an appropriate amount of enzyme-free water was added, solubilized at 65°C for 10 minutes, and the OD value and concentration of RNA were measured. The extracted RNA samples should be stored at -80°C for subsequent use.
[0075] (2) RNA reverse transcription to cDNA
[0076] 500 ng of RNA was reverse transcribed into cDNA using a reverse transcription kit (Takara RR037A).
[0077] (3) Reverse transcription of miRNA:
[0078] Operate on ice, 20 μL per reaction system, as shown in Table 1:
[0079] Table 1
[0080]
[0081] (4) Reverse transcription of mRNA:
[0082] Operate on ice, 20 μL per reaction system, as shown in Table 2:
[0083] Table 2
[0084]
[0085] The reaction procedure was: 37°C for 45 min, 85°C for 5 min, and maintain at 4°C.
[0086] (5) qRT-PCR
[0087] The miRNAs primer sequences were designed according to the miRNAs primer design principles.
[0088] The cDNA obtained by reverse transcription reaction was diluted 1:10 and subjected to the following qRT-PCR reaction.
[0089] Operate on ice, 20 μL per reaction system, as shown in Table 3:
[0090] Table 3
[0091]
[0092] When conducting a real-time quantitative PCR (Real-time PCR) experiment, first mix the reaction solution thoroughly and react in a Real-time PCR instrument according to the following procedure:
[0093] In the first stage (Stage 1), the temperature was set to 95°C for 2 minutes;
[0094] The second stage (Stage 2) was performed for 35 cycles, each cycle consisting of 94°C for 5 seconds and 60°C for 1 minute;
[0095] The third stage (Stage 3) includes 95°C for 15 seconds, 60°C for 1 minute, and then back to 95°C for 5 seconds.
[0096] GAPDH was used as an internal reference gene in the experiment to quantitatively analyze the relative levels of each mRNA, and the expression levels of these mRNAs were expressed by calculating the relative ratios.
[0097] 1.2.3 miRNA sequencing analysis:
[0098] Three naturally aged AC16 cardiomyocytes and three normal control cells were selected. Total RNA was extracted and sent to Guangzhou Epigenetics for miRNA sequencing. MiRNAs with significant expression differences (Fold chang ≥ 2.0, P value < 0.05) were screened, and then qRT-PCR was used to determine the levels of the top 10 miRNAs in the patient's plasma. The marker with the highest expression level was used for the following experiment.
[0099] The results are as follows Figure 1 As shown in Table 4. Figure 1 The heat map of miRNA expression differences between aging cardiomyocytes AC16 and normal controls obtained by sequencing. Table 4 records the top 10 upregulated miRNAs obtained by sequencing data.
[0100] Table 4 Top 10 upregulated miRNAs obtained from sequencing data
[0101]
[0102] 1.2.4ROC curve drawing:
[0103] The receiver operating characteristic (ROC) curve is an analytical tool that shows the diagnostic efficacy of biomarkers by plotting the relationship between the true positive rate (sensitivity) and the false positive rate (1-specificity). In the ROC curve, the ordinate represents sensitivity, that is, the probability of correctly identifying the presence of a disease; the abscissa represents 1-specificity, that is, the probability of incorrectly marking a healthy individual as a disease. By setting different cutoff values, the sensitivity and specificity at each cutoff value are calculated, and then these points are connected into a line to form a ROC curve. The closer the curve is to the upper left corner, the better the performance of the diagnostic marker. In the present invention, we use version 9.1.0 of GraphPad Prism software to draw ROC curves to evaluate the diagnostic ability of specific biomarkers to diseases.
[0104] 1.2.5 Statistical analysis:
[0105] The t-test and variance analysis were used for normal variables, and the Mann Whitney U test and Kruskal Wallis test were used for non-normal variables. Statistical analysis was performed using R software (v 3.4.2) and GraphPad Prism software (v 8.00). Biological replicates are shown as single data points superimposed on the bar graph. P < 0.05 was considered to be significantly different.
[0106] 2. Verification results:
[0107] like Figure 2As shown, the hsa-miR-186-5p content in the plasma of patients with myocardial aging was determined by qRT-PCR. The results showed that the expression of hsa-miR-186-5p in the plasma of patients with myocardial aging was significantly higher than that in the plasma of healthy controls, indicating that hsa-miR-186-5p is a potential biomarker of myocardial aging.
[0108] Figure 3 The ROC curve of hsa-miR-186-5p in diagnosing myocardial aging patients is shown. Figure 3 It can be seen that its specificity and sensitivity are excellent, indicating that hsa-miR-186-5p has good diagnostic efficacy.
[0109] Example 2: Further verification of the relationship between hsa-miR-186-5p and myocardial aging using β-galactosidase staining experiment relation
[0110] 1. Experimental purpose:
[0111] After a limited number of divisions, normal cells stop dividing and irreversible growth arrest occurs. At this time, the cells enter a state of senescence, and the β-galactosidase associated with senescence is activated. β-galactosidase is a hydrolase in the cell lysosome, but the activity of this enzyme is upregulated in senescent cells. Based on this phenomenon and principle, with galactoside as a substrate, senescent cell-specific β-galactosidase catalyzes the substrate to produce a blue product, which is manifested as a blue deposit in the cell cytoplasm. Under an optical microscope, cells or tissues expressing β-galactosidase that have turned blue can be easily observed. The β-galactosidase staining experiment is the gold standard for determining whether cells are senescent in cell molecular experiments.
[0112] 2. Experimental methods:
[0113] To perform β-galactosidase staining on AC16 human cardiomyocytes cultured in 6-well plates, the Beyotime galactosidase staining kit (C0602) was first used. The steps are as follows: First, the cell culture medium was aspirated, and then the cells were washed once with phosphate buffered saline (PBS). Next, 1 ml of β-galactosidase staining fixative was added and fixed at room temperature for 15 minutes. After fixation, the fixative was aspirated, and the cells were washed again with PBS for 3 times, each wash lasting 3 minutes. After washing, the PBS was aspirated, and 1 ml of staining working solution was added to each well. The preparation ratio of the staining working solution was: 10 μl of β-galactosidase staining solution a, 10 μl of β-galactosidase staining solution b, 930 μl of β-galactosidase staining solution c, and 50 μl of X-Gal solution. The 6-well plate was covered with plastic wrap to prevent evaporation of the liquid and incubated overnight at 37°C. Note that this incubation process cannot be performed in a CO2 incubator. Finally, observe the staining results under an ordinary optical microscope.
[0114] 3. Statistical analysis methods:
[0115] Cells stained blue under an optical microscope were regarded as positive cells, and the number of positive cells per 100 cells was randomly selected to determine the positive cell ratio (%). The positive cell ratio of each sample was correlated with hsa-miR-186-5p.
[0116] 4. Experimental results:
[0117] like Figure 4 As shown in the figure, the expression levels of β-galactosidase, a marker of cardiomyocyte senescence, and hsa-miR-186-5p are well correlated. The two are positively correlated, indicating that the relationship between hsa-miR-186-5p and cell senescence is clear and has good diagnostic efficacy.
[0118] Example 3 Experiment on the relationship between BNP and hsa-miR-186-5p expression
[0119] B-type natriuretic peptide (BNP) and its precursor N-terminal pro-B-type natriuretic peptide (NT-proBNP) are key biomarkers for assessing cardiac function, especially in the diagnosis, differential diagnosis, assessment of disease severity and prognosis of heart failure. In healthy adults, the normal level of BNP should be less than 100ng / L, but with age and decreased cardiac function, BNP levels will gradually increase. Generally speaking, BNP levels exceeding 100ng / L are considered abnormal. According to the expert consensus of the American College of Cardiology (ACC) in 2004, when the BNP level is less than 100ng / L, the possibility of heart failure is very small, and the negative predictive value is 90%; when the BNP level is higher than 500ng / L, the possibility of heart failure is very high, and the positive predictive value is also 90%.
[0120] BNP in the heart is mainly distributed in the left and right atria, and the BNP content in the right atrium is about three times that of the left atrium. In contrast, the BNP content in the ventricles is less because the BNP precursor is not stored in the ventricles. Only when the tension of the ventricular wall increases will the high expression of the BNP gene be triggered, and a large amount of BNP will be rapidly synthesized and secreted into the blood. An increase in the level of BNP in plasma usually means that there is an obstruction in the contraction or relaxation function of the heart, resulting in insufficient venous return to the heart, and the ventricles are therefore stretched. Changes in BNP levels are dynamic and can reflect changes in heart function.
[0121] Myocardial aging is a natural process that occurs with aging, which leads to a gradual decline in the function and efficiency of the heart muscle. This decline may weaken the heart's ability to pump blood and affect blood circulation, thereby increasing the release of BNP. Therefore, BNP levels are an important indicator for assessing myocardial aging and heart failure risk, and have important clinical significance for monitoring and managing heart health.
[0122] The experimental method is the same as described in Example 4.
[0123] Experimental results and analysis: Figure 5 The relationship between B-type natriuretic peptide (BNP) and the expression of microRNA hsa-miR-186-5p in the patient's plasma was demonstrated, revealing a positive correlation between the two. BNP is a hallmark protein of heart failure, and its elevated levels are usually associated with heart failure. As a microRNA, hsa-miR-186-5p's level in plasma is positively correlated with the expression level of BNP, indicating that hsa-miR-186-5p may be involved in the regulation of cardiac function. These results indicate that the level of hsa-miR-186-5p in plasma can be used as an indicator of the severity of heart disease, providing a potential biomarker for the diagnosis and monitoring of heart failure. Example 4 In vitro experimental cell level verification Relationship between the expression of hsa-miR-186-5p and myocardial aging
[0124] 1. Materials and Methods
[0125] 1. Cell culture:
[0126] Human cardiomyocyte cell line (AC16) was purchased from Wuhan Pronocell Company. The cells were cultured in RPMI-1640 medium + 10% fetal bovine plasma in an incubator at 37 degrees and 5% carbon dioxide.
[0127] siRNA knockdown method: siRNA was ordered from Thermo Fisher and added according to the instructions when the cell confluence reached 70%. The knockdown effect was determined by qRT-PCR after 24 hours of induction.
[0128] 2. Cell senescence treatment:
[0129] To induce senescence of cardiomyocytes AC 16, these cells were exposed to 10 mM concentration of D-galactose (D-gal) in the experiment. D-galactose, as an effective inducer of aging model, has a stronger glycation effect than glucose and can induce oxidative stress. Under this treatment, D-galactose can induce cytotoxic reactions and aging-related cellular changes, including promoting the increase in the level of B-type natriuretic peptide (BNP) secreted by cardiomyocytes. After 24 hours of treatment, by comparing the cardiomyocytes of the treated group and the untreated control group, the expression levels of intracellular miRNAs and the concentration of BNP in the culture supernatant can be determined to evaluate the cell senescence effect induced by D-galactose.
[0130] 3. The qRT-PCR method is the same as in Example 1.
[0131] 4. Determination of human plasma BNP:
[0132] To determine the creatine kinase isoenzyme (BNP) in plasma, first let the whole blood in the blood collection tube stand at room temperature (37 degrees) for more than half an hour, and then use a centrifuge to centrifuge at 3500 to 4000 rpm for 5 to 10 minutes to separate the plasma. Next, use the BNP ELISA assay kit (ZC-34224) provided by Zhuocai Biotechnology for the experiment. The experimental steps include: first add 100 microliters of sample to each well, and let the kit equilibrate at room temperature for 30 minutes. Subsequently, take out the required strips from the aluminum foil bag, and seal the remaining strips with a ziplock bag and return them to 4°C for storage. For the standard wells, add 50 microliters of different concentrations of standard; add 50 microliters of the sample to be tested to the sample well; and do not add anything to the blank well. In the standard wells and sample wells (except the blank wells), add 100 microliters of horseradish peroxidase (HRP) labeled detection antibody to each well, seal the reaction wells with a sealing film, and then incubate in a water bath or incubator at 37°C for 60 minutes. After incubation, discard the liquid in the wells and pat dry with absorbent paper. Next, add 350 microliters of washing solution to each well, let it stand for 1 minute, then shake off the washing solution and pat dry with absorbent paper. Repeat this washing step for a total of 5 times, or use a plate washer for washing. After washing, add 50 microliters of substrates A and B to each well and incubate at 37°C in the dark for 15 minutes. After incubation, add 50 microliters of stop solution to each well, and measure the absorbance (OD) value of each well using a photometer with a wavelength of 450nm within 15 minutes.
[0133] 5. Flow cytometry experiment:
[0134] During the cell collection and staining process, first remove the culture medium and wash the cells once with phosphate buffered saline (PBS). Next, trypsinize the cells until the cells can be dislodged by gently blowing the pipette or pipette tip. At this time, add the previously collected cell culture medium, blow off any attached cells, and gently blow off the cell clumps. Collect the cells in a centrifuge tube and centrifuge at a centrifugal force of about 1000g for 3-5 minutes to pellet the cells. For some cells that are difficult to pellet, the centrifugation time can be extended or the centrifugal force can be increased appropriately. Carefully aspirate the supernatant, leaving about 50μL of the culture medium to prevent the cells from being aspirated. Then, add 1 ml of PBS pre-cooled to an ice bath to resuspend the cells and transfer the cells to a 1.5ml centrifuge tube. Centrifuge again to pellet the cells, carefully aspirate the supernatant, leaving about 50μL of PBS. Add 1 ml of 70% ethanol, also pre-cooled to an ice bath, gently pipette to mix, and fix at 4°C for 30 minutes. After that, centrifuge at a centrifugal force of about 1000g for 5 minutes to pellet the cells. Add about 1 ml of pre-cooled PBS to resuspend the cells, centrifuge again to precipitate the cells, carefully remove the supernatant, and retain about 50 μL of PBS. Gently tap the bottom of the centrifuge tube to properly disperse the cells to prevent the cells from aggregating. Add 0.5 ml of propidium iodide staining solution to each tube of cell sample, fully resuspend the cell pellet, and incubate at 37°C in the dark for 30 minutes. After incubation, store the cells at 4°C in the dark. Finally, use a flow cytometer to detect red fluorescence at an excitation wavelength of 488 nm and simultaneously detect light scattering to analyze the DNA content and other characteristics of the cells.
[0135] 6. Experimental results:
[0136] Fig. 6A Figure 2 is the expression level of hsa-miR-186-5p after AC16 was transfected with hsa-miR-186-5p small interfering RNA (siRNA). Fig. 6A As can be seen in the figure, the expression level of hsa-miR-186-5p was reduced. Figure 6B Figure 2 is a graph of mRNA expression levels, showing that the total mRNA expression level remained unchanged after AC 16 was transfected with hsa-miR-186-5p small interfering RNA (siRNA). This indicates that the transfection was successful, and subsequent experiments were completed on this basis.
[0137] Fig. 7A and Figure 7B To detect the mRNA expression of two cell senescence markers in AC16 cells after AC16 cells were transfected with hsa-miR-186-5p small interfering RNA (siRNA). Fig. 7A This is a diagram showing the mRNA expression of P21 cell senescence protein markers in AC16 cells. Figure 7BThe figure shows the mRNA expression of IL-1β cell senescence secretion-related phenotype in AC16 cells. It can be seen that after knocking down hsa-miR-186-5p, the expression of P21 and IL-1β mRNA decreased, indicating that knocking down hsa-miR-186-5p can slow down cell senescence, and hsa-miR-186-5p may be used as a therapeutic target for myocardial aging.
[0138] Figure 8 The figure shows the expression of hsa-miR-186-5p and BNP induced by D-gal after knocking down hsa-miR-186-5p and the control group AC16 treated with D-gal. The results show that D-gal-induced aging can cause a significant increase in BNP levels. The expression of hsa-miR-186-5p increased under D-gal-induced aging, while the expression level of BNP decreased after knocking down hsa-miR-186-5p. This indicates that hsa-miR-186-5p plays a role in cardiomyocyte aging, providing evidence for its molecular basis for the treatment of cardiomyocyte aging.
[0139] Fig. 9A and Fig. 9B Flow cytometry was used to determine the cell cycle status of hsa-miR-186-5p knockdown and normal AC16 cells after cell senescence was induced by the senescence-inducing reagent D-gal. Fig. 9A It can be seen that when cells age, the cell DNA loses the ability to divide, and the proportion of cells in the S phase (stagnation period) increases, which is characterized by an increase in the proportion of cells in the S phase in the cell picture. Fig. 9B It can be seen that the proportion of S phase is lower than that of D-gal after knocking down hsa-miR-186-5p. Cell experiments show that the proportion of senescent cells induced by D-gal is reduced after knocking down hsa-miR-186-5p, which indicates that reducing hsa-miR-186-5p effectively antagonizes cell senescence. Therefore, hsa-miR-186-5p may be used as a therapeutic target for myocardial aging.
[0140] The above experimental results show that hsa-miR-186-5p has a significant correlation with myocardial aging and can become a new biological marker for myocardial aging. In the D-galactose (D-gal)-induced cardiomyocyte aging model, the expression level of hsa-miR-186-5p was upregulated, and ROC curve analysis showed that hsa-miR-186-5p has a good ability to diagnose patients with myocardial aging. In addition, the results of flow cytometry revealed that knocking down hsa-miR-186-5p can alleviate D-gal-induced cell senescence, which is manifested as a decrease in the proportion of cells in the S phase of the cell cycle. These findings indicate that hsa-miR-186-5p may be involved in the induction of senescence by D-gal on cardiomyocytes, and reducing its expression can effectively alleviate cell senescence. Therefore, hsa-miR-186-5p is not only expected to become a new diagnostic biomarker for myocardial aging, but also a potential target for the treatment of myocardial aging.
[0141] Example 5 The present invention relates to sequences, primers and kit compositions
[0142] The nucleotide sequence of the myocardial aging marker hsa-miR-186-5p provided by the present invention is shown in SEQ ID No.1.
[0143] SEQ ID No.1: CAAAGAATTCTCCTTTTGGGCT
[0144] The primer pair for specifically recognizing hsa-miR-186-5p provided by the present invention comprises an upstream primer as shown in SEQ ID No. 2 and a downstream primer as shown in SEQ ID No. 3:
[0145] SEQ ID No.2: GTCGTATCCAGTGCAGGGT
[0146] SEQ ID No.3: AACACGCCAAAGAATTCTCCT
[0147] The kit provided by the present invention comprises:
[0148] 5x primer buffer, reaction enzyme combination I, Random 6mers, Oligo dT primer, RNase-free pure water, SYBR probe II (Tl i RNaseH Plus) (2x), PCR Primer (F+R) (10uM), ROX Reference dye (50x).
Claims
1. Application of a substance for detecting miRNA markers, Features Includes one or more of the following applications: A1) Application in the preparation of products for diagnosing myocardial aging; A2) Application in the preparation of products for screening myocardial aging; A3) Application in the preparation of products for treating myocardial aging; A4) Application in the preparation of myocardial aging condition assessment products; A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases; The miRNA marker is hsa-miR-186-5p, and the nucleotide sequence is shown in SEQ ID No.
1.
2. The use according to claim 1, Features: The product is a product for diagnosing myocardial aging by detecting the expression level of hsa-miR-186-5p through RT-PCR, real-time quantitative PCR, in situ hybridization, chip or high-throughput sequencing platform.
3. The use according to claim 1, Features: The substance is a reagent for detecting the expression level of hsa-miR-186-5p, or a reagent for specifically identifying hsa-miR-186-5p, or a reagent for detecting the content of hsa-miR-186-5p.
4. The use according to claim 1, Features: The substance is a substance for detecting hsa-miR-186-5p, including the following a), b) or c) a) primers for detecting or specifically recognizing hsa-miR-186-5p; b) a reagent set containing the reagent described in a); c) A kit containing a) or b).
5. The use according to claim 4, Features: The primers are the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.
3.
6. A kit for detecting miRNA markers, Features Includes one or more of the following applications: A1) Application in the preparation of products for diagnosing myocardial aging; A2) Application in the preparation of products for screening myocardial aging; A3) Application in the preparation of products for treating myocardial aging; A4) Application in the preparation of myocardial aging condition assessment products; A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases; The miRNA marker is hsa-miR-186-5p, and the nucleotide sequence is shown in SEQ ID No.1; the kit includes a reagent for detecting or specifically identifying hsa-miR-186-5p, or a reagent for detecting the expression level of hsa-miR-186-5p.
7. The kit according to claim 6, Features: The reagent for detecting or specifically identifying hsa-miR-186-5p is a specific primer, and the specific primer is the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.
3.
8. A primer for detecting a miRNA marker, Features Includes one or more of the following applications: A1) Application in the preparation of products for diagnosing myocardial aging; A2) Application in the preparation of products for screening myocardial aging; A3) Application in the preparation of products for treating myocardial aging; A4) Application in the preparation of myocardial aging condition assessment products; A5) Application in the preparation of products for distinguishing myocardial aging from other heart diseases; The primers are primers for detecting the expression level of hsa-miR-186-5p or specifically identifying hsa-miR-186-5p, the miRNA marker is hsa-miR-186-5p, and the nucleotide sequence is shown in SEQ ID No.
1.
9. The primer according to claim 8, Features: The primers are the upstream primer shown in SEQ ID No.2 and the downstream primer shown in SEQ ID No.3.
Citation Information
Cited By
PiRNA (piribose nucleic acid) marker for diagnosing and evaluating vascular senescence, kit and application of piRNA marker
CN120519565A
